US FDA approves AstraZeneca's breast cancer drug combination
The U.S. Food and Drug Administration on Thursday approved AstraZeneca's drug capivasertib in combination with an older drug, providing another treatment option for patients with the most common ty...
CDC releases 77,000 additional doses of Sanofi-AstraZeneca's RSV drug
The U.S. Centers for Disease Control and Prevention said on Thursday it has released more than 77,000 additional doses of Sanofi and AstraZeneca's respiratory syncytial virus (RSV) drug Beyfortus.
AstraZeneca to learn from latest Imfinzi trial after endpoint not met
AstraZeneca said a trial of its Imfinzi drug as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy (CRT) failed to make a statistically significant differenc...
AstraZeneca's Imfinzi plus chemoradiotherapy fail main goal in late stage trial
Drugmaker AstraZeneca said on Tuesday its cancer drug Imfinzi administered with chemoradiotherapy failed to meet its main goal in a late-stage trial to treat unresectable, Stage 3 non-small cell lu...
AstraZeneca prioritizes US for RSV drug amid surge in cases
AstraZeneca on Friday said it was prioritizing the U.S. market for additional doses of its respiratory syncytial virus (RSV) drug Beyfortus, which was approved in July to prevent the disease in inf...
AstraZeneca (AZN) Beats on Q3 Earnings & Sales, Ups 2023 View
AstraZeneca (AZN) beats third-quarter estimates for earnings and sales. The company raises its sales and EPS guidance for 2023.
AstraZeneca (AZN) Buys Global Rights to Oral Obesity Candidate
To cash in on the rising demand for obesity drugs, AstraZeneca (AZN) in-licenses exclusive rights to ECC5004, a novel oral GLP-1RA therapy, from private Chinese biotech Eccogene.
The 7 Next Trillion Dollar Companies to Invest in to Become a Millionaire
Millionaires, by investing in equities, are not made overnight. It takes years of grinding in the form of research that a high level of patience should back.
AstraZeneca CEO discusses oral weight loss drug agreement with Eccogene
AstraZeneca (AZN) is re-entering the weight loss drug market through a new partnership with China's Eccogene. The deal provides AstraZeneca with global rights, excluding China, to develop and comme...
AstraZeneca PLC (AZN) Q3 2023 Earnings Call Transcript
AstraZeneca PLC (NASDAQ:AZN ) Q3 2023 Earnings Conference Call November 9, 2023 9:00 AM ET Corporate Participants Andy Barnett - Head, Investor Relations Pascal Soriot - Chief Executive Officer Ara...
Jobless Claims Decreased More Than Expected
Pre-market futures again are coming in slightly higher, working through a two-week period (so far) of generally higher market indices. Although the Dow broke an eight-day winning streak yesterday, ...
AstraZeneca Strikes a Deal for an Experimental Weight-Loss Drug and Boosts Its Guidance
AstraZeneca (AZN) announced a deal for an experimental weight-loss pill and raised its guidance on higher demand for its cancer treatments.
AstraZeneca CFO: Obesity Market Has a Lot of Potential
AstraZeneca CFO Aradhana Sarin discusses the company's third-quarter results and its plans to develop an obesity pill. The treatment developed by closely held Chinese biotech Eccogene is in early-s...
AstraZeneca faces lawsuits in High Court over ‘defective' Covid-19 vaccine
A UK father and a widower have filed lawsuits against AstraZeneca PLC (LSE:AZN), claiming that the Oxford-AstraZeneca Covid-19 vaccine was defective and caused blood clots and brain injuries to the...
Astrazeneca (AZN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Stree...
Related Companies